Gut Bacterial Infection Triggers Parkinson's-Like Pathology in Mice Carrying LRRK2 Mutation
Researchers found that recurrent gut bacterial infection in mice carrying the LRRK2 G2019S mutation—a common genetic risk factor for Parkinson's disease—induces progressive Parkinson's-like symptoms and neurodegeneration, while unaffected mice remain resistant. The study demonstrates a gene-environment interaction where the mutation amplifies inflammatory responses to intestinal infection rather than impairing immune defense. This finding supports the gut-brain axis hypothesis and suggests environmental triggers may be necessary for disease progression in genetically predisposed individuals.
In a preprint study, researchers established a mouse model combining the LRRK2 G2019S genetic mutation with recurrent Citrobacter rodentium infection to investigate how environmental factors trigger Parkinson's disease. Mice carrying the mutation developed progressive motor impairment, reduced activity, coordination problems, and selective dopamine neuron loss in the brain—hallmarks of Parkinson's—while genetically normal mice showed resistance to the same infection. The mechanism involved exacerbated intestinal inflammation, barrier dysfunction, and increased intestinal permeability in mutant mice, along with accumulation of pathological alpha-synuclein protein in the gut that extended beyond the epithelial layer. Notably, the mutant mice cleared bacteria normally, indicating the LRRK2 mutation amplifies inflammatory signaling rather than weakening antimicrobial immunity. These findings establish a physiologically relevant model linking intestinal inflammation to neurodegeneration through the gut-brain axis and suggest that genetic predisposition requires environmental triggers for Parkinson's disease manifestation.
What's missing
The study's limitations and open questions include: whether findings in this specific mouse infection model translate to human Parkinson's disease pathogenesis; the generalizability to other LRRK2 mutations or genetic forms of Parkinson's; long-term progression and reversibility of pathology; and whether therapeutic interventions targeting intestinal inflammation could prevent or reverse neurodegeneration in this model.
What different sources said
- bioRxivCenter
Gut bacterial Infection drives Parkinsonian pathology in LRRK2 G2019S Knock-in Mice
Related
Study Shows Statins Reduce Coenzyme Q in Brain Cells, Impairing Mitochondrial Function
A laboratory study found that statin drugs decrease coenzyme Q levels in astrocytes (brain support cells) by 30-40%, reducing their mitochondrial energy production and increasing oxidative stress. Astrocytes are critical for maintaining brain health and protecting neurons from damage. The findings suggest CoQ10 supplementation may help counteract these effects, though human clinical evidence remains limited.
Study reveals zebrafish larvae exhibit slowly fluctuating directional swim biases driven by internal dynamics
Researchers found that 5-day-old zebrafish larvae display changing directional swim preferences over many hours even in stable environments, contrary to classical models assuming constant individual biases. Computational analysis suggests these fluctuations arise from a non-stationary Markovian process with two independent internal input streams modulating swim direction repetition. The findings suggest animals possess intrinsic mechanisms for generating behavioral variability independent of external stimuli, with implications for understanding how internal states shape adaptive behavior.
Two Small Molecules Show Promise as Broad-Spectrum Coronavirus Inhibitors in Laboratory Study
Researchers found that sennoside A and ceftazidime, two small molecules, can inhibit RNA binding in the nucleocapsid proteins of SARS-CoV-2, SARS-CoV, and MERS-CoV in laboratory experiments. The nucleocapsid protein is highly conserved across coronaviruses and essential for viral replication, making it a potential drug target. The findings suggest these compounds could form the basis for pan-coronavirus antiviral therapies, though further development and clinical testing would be needed.